134.64 0.00 (0.00%)
After hours: 4:34PM EDT
|Bid||134.55 x 1100|
|Ask||134.61 x 800|
|Day's Range||132.33 - 135.42|
|52 Week Range||97.38 - 141.98|
|Beta (3Y Monthly)||1.30|
|PE Ratio (TTM)||35.70|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.
With WellSky's newest acquisition, the Overland Park health IT company folds in a large home care player that has access to more than 470 care centers throughout the U.S.
Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.
The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.
Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.